Taiho Pharmaceutical and Phost’in Therapeutics announce an Option and License Agreement on the First-in-Class GnT-V inhibitor PhOx430

Tokyo (Japan) and Montpellier, France – August 2023, 25th Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Phost’in Therapeutics SAS (Phost’in) today announced that the two companies have entered into an option and license agreement through which Taiho Pharmaceutical will obtain option rights to in-license PhOx430, a First-in-Class small molecule targeting GnT-V (N-acetylglucosaminyltransferase-V). Download the full Press Release

The release as fetched from its publisher. phostin.com ↗